Are You Considering SOT for Lyme Disease?

“What do you think about SOT?”

She looked at me earnestly. She had already been through two rounds of antibiotics, herbal protocols, and a year of chronic symptoms.

“I know it’s expensive, but people are saying it helps. Should I try it?”

It wasn’t the first time I’d been asked.

Patients often come to me with questions about experimental or emerging therapies—especially after exhausting standard treatments for Lyme disease. One that’s been generating attention lately is Supportive Oligonucleotide Therapy (SOT).

Some patients say it changed their lives. Others say it did nothing—or even made them worse. So what exactly is SOT, and what does the science actually say?

What Is SOT Therapy?

Supportive Oligonucleotide Therapy involves a lab-designed oligonucleotide—essentially a short strand of synthetic genetic material—that binds to a specific RNA or DNA sequence of a targeted microbe.

In Lyme disease, the goal is to inhibit the expression of bacterial genes believed to be important for Borrelia burgdorferi survival.

This therapy was originally developed in oncology settings but has since been adapted for infections such as Lyme disease, Epstein–Barr virus (EBV), and Herpes Simplex Virus (HSV).

SOT is typically administered intravenously and customized for each patient based on PCR testing.

Unlike antibiotics, SOT is designed to act more selectively rather than targeting bacterial cell walls or metabolism directly.

Preliminary Evidence: What One Study Found

Apostolou and colleagues published a small exploratory study evaluating SOT in patients with viral infections and Lyme disease.¹

The study analyzed 115 patients, including a subset with Lyme disease.

• SOT targeted the outer surface proteins OspA and OspB associated with Borrelia burgdorferi
• The authors reported a statistically significant reduction in DNA copy numbers after one or two SOT treatments
• The researchers concluded that SOT “might be beneficial” for Lyme disease and certain viral infections

Important Limitations of the Study

The study also had several important limitations:

• It did not assess whether patients actually felt better clinically
• It focused on PCR findings rather than symptom improvement
• Safety and adverse effects were not systematically evaluated
• Co-infections and overlapping chronic illnesses were not addressed
• The role of biofilms or persister forms of Borrelia was not explored

Laboratory findings and meaningful clinical recovery are not always the same thing.

A reduction in DNA copy number does not automatically translate into symptom improvement, functional recovery, or long-term benefit.

Additionally, the SOT used in the study was manufactured by RGCC Labs in Greece, a facility not regulated by the U.S. FDA.

The therapy is currently offered through a limited number of clinics and is typically paid for out-of-pocket.

Do I Prescribe SOT in My Practice?

At this time, I do not prescribe Supportive Oligonucleotide Therapy (SOT) in my practice.

Many patients are understandably drawn to emerging therapies, especially after years of persistent symptoms or incomplete recovery.

While I remain open to new approaches, I also believe it’s important to balance openness with caution and ground decisions in the available evidence.

Right now, there is not enough peer-reviewed clinical outcome data for me to confidently recommend SOT as part of a standard Lyme disease treatment plan.

I continue to follow the evolving science closely and remain open to promising therapies as better evidence becomes available.

In the meantime, I focus on care supported by both research and clinical experience—tailoring treatment to the individual patient while considering persistent infection, immune dysregulation, inflammation, autonomic dysfunction, co-infections, and the emotional toll of chronic illness.

What I Tell My Patients About SOT

When patients ask about SOT, I start by looking carefully at the full picture of their illness.

Have all possible causes of symptoms been explored? Are there overlooked co-infections, autonomic problems, sleep disorders, inflammatory triggers, or other conditions contributing to illness?

Sometimes patients are searching for the next therapy when what they really need is a deeper reassessment of the foundation.

In many cases, we don’t need to go further. We need to go deeper.

Bottom Line

Supportive Oligonucleotide Therapy represents an interesting experimental approach for Lyme disease and certain chronic infections.

However, current evidence remains preliminary.

• Only limited research has evaluated SOT for Lyme disease
• Existing studies focus primarily on PCR findings rather than symptom improvement
• Safety and long-term outcomes remain uncertain
• SOT should not replace careful clinical evaluation and individualized treatment planning

SOT may eventually have a role in Lyme disease care, but at this stage it should be viewed as experimental rather than established.

If you are considering SOT, it’s important to speak with a clinician who understands the broader picture—including Lyme disease, co-infections, immune dysfunction, autonomic symptoms, and other possible contributors to chronic illness.

Frequently Asked Questions

What is SOT therapy for Lyme disease?

SOT (Supportive Oligonucleotide Therapy) is an experimental therapy designed to target genetic material associated with microbes such as Borrelia burgdorferi.

Does SOT cure Lyme disease?

There is currently not enough clinical evidence to conclude that SOT cures Lyme disease.

Has SOT been studied scientifically?

Only limited preliminary research has been published, and existing studies focus mainly on laboratory findings rather than patient outcomes.

Is SOT FDA approved?

The SOT discussed in Lyme disease treatment settings is not FDA approved.

Why are patients interested in SOT?

Many patients pursue SOT after persistent symptoms, incomplete recovery, or frustration with standard treatment approaches.

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention